Table 3.
Antibiotic Resistance Characteristics Of The 12 NDM-5-Positive K. pneumoniae Isolates And Their Corresponding Transconjugants
| Isolate No. | Antimicrobial Resistance Genes | Minimum Inhibitory Concentration (μg/mL) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MEM | IPM | ATM | CTX | CAZ | FEP | AM | CPFX | LE | AMC | TZP | SCF | SMZ-TMP | TG | PB | ||
| KP1 | blaNDM-5, SHV-11, TEM-1 | 8 | ≥16 | ≥64 | ≥64 | ≥64 | ≥32 | ≤2 | 0.5 | 1 | ≥32 | ≥128 | ≥64 | ≤20 | 2 | ≤0.5 |
| KP2 | blaNDM-5, SHV-11, TEM-1 | ≥16 | ≥16 | 16 | ≥64 | ≥64 | ≥32 | ≤2 | ≤0.25 | ≤0.12 | ≥32 | ≥128 | ≥64 | ≤20 | ≤0.5 | ≤0.5 |
| KP3 | blaNDM-5, SHV-11, TEM-1 | ≥16 | ≥16 | ≥64 | ≥64 | ≥64 | ≥32 | ≤2 | 1 | 1 | ≥32 | ≥128 | ≥64 | ≤20 | 2 | ≤0.5 |
| KP4 | blaNDM-5, SHV-11, TEM-1 | ≥16 | ≥16 | ≥64 | ≥64 | ≥64 | ≥32 | ≤2 | 0.5 | 1 | ≥32 | ≥128 | ≥64 | ≤20 | 2 | ≤0.5 |
| KP5 | blaNDM-5, SHV-11, TEM-1 | ≥16 | ≥16 | ≥64 | ≥64 | ≥64 | ≥32 | ≤2 | ≤0.25 | ≤0.12 | ≥32 | ≥128 | ≥64 | ≤20 | 2 | ≤0.5 |
| KP6 | blaNDM-5, SHV-11, TEM-1 | ≥16 | ≥16 | ≥64 | ≥64 | ≥64 | ≥32 | ≤2 | 0.5 | 1 | ≥32 | ≥128 | ≥64 | ≤20 | 2 | ≤0.5 |
| KP7 | blaNDM-5, SHV-11, TEM-1 | ≥16 | ≥16 | ≥64 | ≥64 | ≥64 | ≥32 | ≤2 | 0.5 | 1 | ≥32 | ≥128 | ≥64 | ≤20 | 2 | ≤0.5 |
| KP8 | blaNDM-5, SHV-11, TEM-1 | ≥16 | ≥16 | ≥64 | ≥64 | ≥64 | ≥32 | ≤2 | 1 | 1 | ≥32 | ≥128 | ≥64 | ≤20 | 2 | ≤0.5 |
| KP9 | blaNDM-5, SHV-11, TEM-1 | ≥16 | ≥16 | ≥64 | ≥64 | ≥64 | ≥32 | ≤2 | 0.5 | 1 | ≥32 | ≥128 | ≥64 | ≤20 | 2 | ≤0.5 |
| KP10 | blaNDM-5, SHV-11, TEM-1 | 8 | ≥16 | ≥64 | ≥64 | ≥64 | ≥32 | ≤2 | ≤0.25 | ≤0.25 | ≥32 | ≥128 | ≥64 | ≤20 | 2 | ≤0.5 |
| KP11 | blaNDM-5, SHV-11, TEM-1 | ≥16 | ≥16 | ≥64 | ≥64 | ≥64 | ≥32 | ≤2 | 0.5 | 1 | ≥32 | ≥128 | ≥64 | ≤20 | 2 | ≤0.5 |
| KP12 | blaNDM-5, SHV-11, TEM-1 | ≥16 | ≥16 | ≥64 | ≥64 | ≥64 | ≥32 | ≤2 | 0.5 | 1 | ≥32 | ≥128 | ≥64 | ≤20 | 2 | ≤0.5 |
| EC600-1 | blaNDM-5 | 8 | ≥16 | ≤1 | ≥64 | ≥64 | 4 | ≤2 | ≤0.25 | ≤0.12 | ≥32 | ≥128 | ≥64 | ≤20 | ≤0.5 | ≤0.5 |
| EC600-2 | blaNDM-5 | 8 | 8 | ≤1 | ≥64 | ≥64 | 4 | ≤2 | 0.5 | ≤0.12 | ≥32 | ≥128 | ≥64 | ≤20 | ≤0.5 | ≤0.5 |
| EC600-3 | blaNDM-5 | 8 | ≥16 | ≤1 | ≥64 | ≥64 | 4 | ≤2 | ≤0.25 | ≤0.12 | ≥32 | ≥128 | ≥64 | ≤20 | ≤0.5 | ≤0.5 |
| EC600-4 | blaNDM-5 | ≥16 | ≥16 | ≤1 | ≥64 | ≥64 | 8 | ≤2 | 0.5 | ≤0.12 | ≥32 | ≥128 | ≥64 | ≤20 | ≤0.5 | ≤0.5 |
| EC600-5 | blaNDM-5 | 8 | ≥16 | ≤1 | ≥64 | ≥64 | 8 | ≤2 | 0.5 | ≤0.12 | ≥32 | ≥128 | ≥64 | ≤20 | ≤0.5 | ≤0.5 |
| EC600-6 | blaNDM-5 | ≥16 | ≥16 | ≤1 | ≥64 | ≥64 | 8 | ≤2 | 0.5 | ≤0.12 | ≥32 | ≥128 | ≥64 | ≤20 | ≤0.5 | ≤0.5 |
| EC600-7 | blaNDM-5 | 4 | ≥16 | ≤1 | ≥64 | ≥64 | 8 | ≤2 | 0.5 | ≤0.12 | ≥32 | ≥128 | ≥64 | ≤20 | ≤0.5 | ≤0.5 |
| EC600-8 | blaNDM-5 | ≥16 | ≥16 | ≤1 | ≥64 | ≥64 | 4 | ≤2 | ≤0.25 | ≤0.12 | ≥32 | ≥128 | ≥64 | ≤20 | ≤0.5 | ≤0.5 |
| EC600-9 | blaNDM-5 | 4 | ≥16 | ≤1 | ≥64 | ≥64 | 4 | ≤2 | 0.5 | ≤0.12 | ≥32 | ≥128 | ≥64 | ≤20 | ≤0.5 | ≤0.5 |
| EC600-10 | blaNDM-5 | 8 | ≥16 | ≤1 | ≥64 | ≥64 | 4 | ≤2 | ≤0.25 | ≤0.12 | ≥32 | ≥128 | ≥64 | ≤20 | ≤0.5 | ≤0.5 |
| EC600-11 | blaNDM-5 | 4 | ≥16 | ≤1 | ≥64 | ≥64 | 8 | ≤2 | 0.5 | ≤0.12 | ≥32 | ≥128 | ≥64 | ≤20 | ≤0.5 | ≤0.5 |
| EC600-12 | blaNDM-5 | 8 | ≥16 | ≤1 | ≥64 | ≥64 | 4 | ≤2 | ≤0.25 | ≤0.12 | ≥32 | ≥128 | ≥64 | ≤20 | ≤0.5 | ≤0.5 |
| EC600 | ≤1 | ≤1 | ≤1 | ≤1 | ≤1 | ≤1 | ≤2 | ≤0.25 | ≤0.12 | 2 | 2 | 2 | ≤20 | ≤0.5 | ≤0.5 | |
Abbreviations: MEM, meropenem; IPM, imipenem; ATM, aztreonam; CAZ, ceftazidime; CTX, cefotaxime; FEP, cefepime; AM, amikacin; CPFX, ciprofloxacin; LE, levofloxacin; AMC, amoxicillin-clavulanate; TZP, piperacillin/tazobactam; SCF, sulbactam/cefoperazone; SMZ-TMP, compound Sulfamethoxazole; TG, tigecycline; PB, polymixin B.